NASDAQ$CABA
Cabaletta Bio Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2023, and provided a business update.
Cabaletta Bio reported its third quarter 2023 financial results, highlighting the expansion of its CABA-201 clinical development program and progress towards initial clinical data in lupus and myositis trials, while also noting that cash, cash equivalents, and short-term investments are expected to support operations into the fourth quarter of 2025.
- Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients.
- Expanded CABA-201 clinical development program within rheumatology and into neurology with additional IND clearances in systemic sclerosis and generalized myasthenia gravis.
- CABA-201 now being evaluated in four concurrent Phase 1/2 studies, each with an initial dose of 1 x 106 cells/kg and a parallel cohort design to accelerate development.
- Cash, cash equivalents and short-term investments expected to support operations into the fourth quarter of 2025.
Headline financials
Revenue & EPS history
Cabaletta Bio · Revenue · Quarterly
$0
Forward guidance
Cabaletta Bio expects to report initial clinical data from Phase 1/2 trials in lupus and/or myositis in the first half of 2024 and anticipates cash, cash equivalents, and short-term investments will fund operations into the fourth quarter of 2025.
Tailwinds
- Initial clinical data from Phase 1/2 trials in lupus and/or myositis expected in the first half of 2024.
- First lupus clinical site actively recruiting patients.
- Expanded CABA-201 clinical development program within rheumatology and into neurology.
- Additional IND clearances in systemic sclerosis and generalized myasthenia gravis.
- Cash, cash equivalents and short-term investments expected to support operations into the fourth quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+2.7%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+5.3%
Avg return
30 days after
67%
16 / 24 earnings
Positive
+22.7%
Q3 2022
Best reaction
-24.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -7.8% | -9.0% | -16.2% | |
| Q3 2025 | -5.0% | -9.4% | -5.1% | |
| Q1 2025 | -0.6% | +6.9% | -2.9% | |
| Q4 2024 | +12.8% | -28.4% | -14.8% | |
| Q3 2024 | -24.4% | -36.7% | -29.7% | |
| Q1 2024 | +12.4% | +14.7% | -5.1% | |
| Q4 2023 | -4.2% | -6.4% | -26.4% | |
| Q3 2023 | +4.0% | +1.6% | -5.6% | |
| Q2 2023 | +10.0% | +10.4% | +12.0% | |
| Q1 2023 | +1.6% | +7.0% | -1.2% | |
| Q4 2022 | +9.3% | +4.3% | +5.4% | |
| Q3 2022 | +22.7% | +84.0% | +207.2% | |
| Q2 2022 | +19.5% | +17.2% | -26.3% | |
| Q1 2022 | +21.1% | +52.8% | -3.3% | |
| Q4 2021 | +14.6% | +32.7% | +6.4% | |
| Q3 2021 | +2.4% | -5.3% | -19.1% | |
| Q2 2021 | +2.0% | +1.9% | +58.0% | |
| Q1 2021 | -6.6% | -14.0% | -7.2% | |
| Q4 2020 | +1.7% | -4.0% | -8.7% | |
| Q3 2020 | +6.7% | +7.1% | +19.3% | |
| Q2 2020 | +6.4% | +4.6% | -15.8% | |
| Q1 2020 | -9.3% | -8.0% | -8.0% | |
| Q4 2019 | +0.3% | -7.6% | +10.7% | |
| Q3 2019 | -23.7% | -38.7% | +3.7% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro